On This Day in Health: March 9, 2023
On March 9, 2023, the United States Food and Drug Administration approved zavegepant nasal spray, marketed as Zavzpret, for the acute treatment of migraine with or without aura in adults. The drug targeted the calcitonin gene-related peptide receptor, commonly known as the CGRP receptor. It brought that mechanism into a nasal formulation for treating an attack that was already occurring. Pfizer announced the authorization the following day, a difference that can make the anniversary date easy to misidentify. The regulatory decision belongs to March 9; the March 10 company release describes the same approval after it had been granted.
Migraine can involve much more than head pain. Nausea and sensitivity to light or sound are among the symptoms that can disrupt daily activity, while some people experience aura around an attack. A nasal route provided an alternative to swallowing a tablet, which can be a practical consideration when nausea accompanies the illness. The development also reflected a more targeted understanding of migraine biology. CGRP signaling had become an important area of treatment research, and blocking its receptor offered an approach different from several older medicines. The new formulation expanded the range of delivery options without establishing that every person with migraine would respond in the same way.
The approval drew on two pivotal placebo-controlled studies. Researchers assessed freedom from pain and freedom from a participant's most bothersome associated symptom two hours after a single dose. Those endpoints were deliberately specific: relief from one feature of an attack is not the same as preventing every future attack or eliminating the underlying condition. The clinical evidence concerned an acute treatment, not an authorization for migraine prevention. Participants in the studies represented defined trial populations, and the findings needed to be interpreted within those designs. The medicine's usefulness was therefore described through measurable outcomes after treatment, alongside prescribing information addressing adverse effects and appropriate use.
Zavegepant's approval illustrates how progress can involve the route of delivery as well as a drug's biological target. An additional option can matter when a familiar formulation is difficult to use or does not meet a patient's needs. At the same time, a new spray does not remove the need to understand the pattern of migraine, distinguish treatment goals, and evaluate the options available. March 9 marks a regulatory milestone in that continuing history, while the next day's announcement marks its public presentation by the manufacturer. Keeping those moments separate preserves an accurate timeline. The lasting significance is an expanded choice within acute migraine care, supported by trials that asked clearly defined questions about what happened after a treated attack.
The FDA's original approval date was March 9. Pfizer's March 10 announcement should not shift the anniversary by one day.
The drug blocked the CGRP receptor through a nasal formulation. It added a delivery option within an established area of migraine research.
Trials measured pain freedom and relief from the most bothersome associated symptom at two hours. Each endpoint described a specific treatment outcome.
The authorization concerned acute attacks. It did not establish the spray as a preventive treatment for future migraine episodes.
A nonoral route can be relevant when an attack includes nausea. Delivery method is part of how a treatment fits a patient's circumstances.
Another option expands choice without guaranteeing identical responses. The milestone belongs within the continuing development of individualized migraine care.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.